新股消息 | 德适生物港股IPO招股书失效

Group 1 - The core point of the article is that Hangzhou Deshi Biotechnology Co., Ltd. (referred to as Deshi Biotechnology) submitted its Hong Kong IPO prospectus on June 29, which has now expired after six months on December 29, with Huatai International as the sole sponsor at the time of submission [1] - The prospectus indicates that Deshi Biotechnology's self-developed iMedImage is the largest general-purpose medical imaging base model in terms of parameter scale globally, which has been successfully commercialized [1] - iMedImage is recognized as the world's first commercialized cross-modal medical imaging base model [1]